Literature DB >> 10902757

A novel missense mutation (C30S) in the gene encoding tumor necrosis factor receptor 1 linked to autosomal-dominant recurrent fever with localized myositis in a French family.

C Dodé1, T Papo, C Fieschi, C Pêcheux, E Dion, F Picard, P Godeau, J Bienvenu, J C Piette, M Delpech, G Grateau.   

Abstract

OBJECTIVE: To characterize both phenotypic (clinical features and magnetic resonance imaging [MRI] findings) and genotypic aspects of autosomal-dominant recurrent fever, also known as tumor necrosis factor receptor (TNFR)-associated periodic syndrome (TRAPS), in a French family and to investigate the role of the mutated 55-kd tumor necrosis factor alpha (TNFalpha) receptor (TNFR1) in the pathogenesis of the disease.
METHODS: The coding region of TNFR1 was sequenced in 2 individuals with TRAPS (the propositus and her grandfather) and in 3 clinically unaffected relatives. Expression of soluble TNFR1 (sTNFR1) was investigated in 3 of the family members carrying a C30S mutation in TNFR1, and was compared with the levels of soluble TNFR2 (sTNFR2) by enzyme-linked immunosorbent assay. The membrane TNFR1 expression was then compared with membrane TNFR2 levels at the surface of peripheral blood mononuclear cells by flow cytometric analysis. The clinical heterogeneity in this French family was investigated by searching polymorphic variants in the TNFalpha promoter by DNA sequencing.
RESULTS: Both the disease course and the clinical presentation in the propositus were highly indicative of TRAPS. MRI study of the segmental inflammatory process in the limbs showed abnormal signals in the muscle and subcutaneous tissue without involvement of adjacent joints or fascia. A novel missense mutation, C30S, in the first extracellular N-terminal cysteine-rich domain (CRD1) of TNFR1 was characterized in the propositus, her affected grandfather, and her clinically unaffected father. Expression of membrane TNFR1 at the surface of monocytes and polymorphonuclear leukocytes, as well as the levels of sTNFR1 in serum when the disease was not active were not modified in the 3 individuals carrying the TNFR1 C30S mutation. In contrast, during attacks, sTNFR1 levels remained abnormally low, as compared with the levels in unrelated patients with active adult-onset systemic Still's disease. The clinical heterogeneity could not be explained by a polymorphic variant in the TNFalpha promoter.
CONCLUSION: TRAPS is a distinct clinical and radiologic disease entity that is responsible for recurrent fever and migratory cellulitis-like processes with localized myositis. We have identified a novel TNFR1 mutation, C30S, that is located in the CRD1 domain in a French family affected by the disease. This mutation seems to affect the level of sTNFR1, which did not increase in the propositus during inflammatory attacks.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10902757     DOI: 10.1002/1529-0131(200007)43:7<1535::AID-ANR18>3.0.CO;2-C

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Autoinflammatory disorders and patients with isolated serosal involvement.

Authors:  Luca Cantarini; Orso Maria Lucherini; Rolando Cimaz; Maria Giuseppina Brizi; Mauro Galeazzi
Journal:  Rheumatol Int       Date:  2010-05-22       Impact factor: 2.631

2.  The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.

Authors:  I Aksentijevich; J Galon; M Soares; E Mansfield; K Hull; H H Oh; R Goldbach-Mansky; J Dean; B Athreya; A J Reginato; M Henrickson; B Pons-Estel; J J O'Shea; D L Kastner
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

3.  Intestinal pseudo-obstruction as a manifestation of tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Isabelle Marie; Fabien Hervé; Catherine Dodé; Jacques Bernet; Hervé Levesque
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

4.  Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series.

Authors:  Luca Cantarini; Orso Maria Lucherini; Rolando Cimaz; Donato Rigante; Cosima Tatiana Baldari; Franco Laghi Pasini; Mauro Galeazzi
Journal:  Rheumatol Int       Date:  2010-05-15       Impact factor: 2.631

5.  Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene.

Authors:  N Ravet; S Rouaghe; C Dodé; J Bienvenu; J Stirnemann; P Lévy; M Delpech; G Grateau
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

Review 6.  TNF-receptor-associated periodic syndrome (TRAPS): an autosomal dominant multisystem disorder.

Authors:  Nima Rezaei
Journal:  Clin Rheumatol       Date:  2006-01-26       Impact factor: 2.980

Review 7.  Autoinflammatory diseases in childhood, part 1: monogenic syndromes.

Authors:  María Navallas; Emilio J Inarejos Clemente; Estíbaliz Iglesias; Mónica Rebollo-Polo; Faizah Mohd Zaki; Oscar M Navarro
Journal:  Pediatr Radiol       Date:  2020-02-17

8.  Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour.

Authors:  Ian Todd; Paul M Radford; Kelly-Ann Draper-Morgan; Richard McIntosh; Susan Bainbridge; Peter Dickinson; Lama Jamhawi; Marios Sansaridis; Mary L Huggins; Patrick J Tighe; Richard J Powell
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

9.  Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response.

Authors:  Juan I Aróstegui; Pilar Solís; Anna Aldea; Teresa Cantero; Josefa Rius; Pilar Bahíllo; Susana Plaza; Jordi Vives; Samuel Gómez; Jordi Yagüe
Journal:  Eur J Pediatr       Date:  2004-11-10       Impact factor: 3.183

10.  TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept.

Authors:  Adriana A Jesus; João B Oliveira; Ivona Aksentijevich; Erika Fujihira; Magda M S Carneiro-Sampaio; Alberto J S Duarte; Clovis A A Silva
Journal:  Eur J Pediatr       Date:  2008-04-12       Impact factor: 3.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.